BEPO-A

LG Life Sciences · Phase 1 active Small molecule

At a glance

Generic name	BEPO-A
Sponsor	LG Life Sciences
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety of F14 Following Total Knee Replacement (PHASE2, PHASE3)
Safety and Activity of F14 for Management of Pain Following Total Knee Replacement (PHASE2)
Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BEPO-A CI brief — competitive landscape report
BEPO-A updates RSS · CI watch RSS
LG Life Sciences portfolio CI